# Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment

> **NCT00087958** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 168 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** XRP9881

## Key facts

- **NCT ID:** NCT00087958
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2007-02
- **Final completion:** 2009-04
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2009-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087958, "Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00087958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*